Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Centessa Pharmaceuticals plc
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
August 27, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 21, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
August 13, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
June 10, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 21, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
May 13, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
April 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
March 28, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
February 09, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
January 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
December 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
December 10, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
November 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
October 31, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
October 30, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
October 25, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
October 03, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
August 23, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
August 14, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
July 10, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 24, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
May 22, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
May 12, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
March 30, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
March 27, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Tickers
CNTA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.